Clinical Trial Update: ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing ICP-022 to chlorambucil plus rituximab in untreated CLL/SLL is underway, with status currently unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• Chlorambucil (chlorambucil)
• ICP-022
• Rituximab (rituximab)

Snippet

Sponsor: Beijing InnoCare Pharma Tech Co., Ltd. | Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 3 | Status: UNKNOWN